Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MARGARET SPITZ and XIFENG WU.
MARGARET SPITZ
Connection Strength
15.276
XIFENG WU
  1. Variants in inflammation genes are implicated in risk of lung cancer in never smokers exposed to second-hand smoke. Cancer Discov. 2011 Oct; 1(5):420-9.
    View in: PubMed
    Score: 0.416
  2. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics. 2008 Nov; 18(11):955-65.
    View in: PubMed
    Score: 0.342
  3. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst. 2008 Nov 05; 100(21):1552-6.
    View in: PubMed
    Score: 0.342
  4. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol. 2007 Nov 01; 25(31):4974-81.
    View in: PubMed
    Score: 0.319
  5. Interplay between mutagen sensitivity and epidemiological factors in modulatinglung cancer risk. Int J Cancer. 2007 Jun 15; 120(12):2687-95.
    View in: PubMed
    Score: 0.311
  6. Mutagen sensitivity: a genetic predisposition factor for cancer. Cancer Res. 2007 Apr 15; 67(8):3493-5.
    View in: PubMed
    Score: 0.308
  7. Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res. 2006 Dec 01; 12(23):7194-201.
    View in: PubMed
    Score: 0.300
  8. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006 Mar; 78(3):464-79.
    View in: PubMed
    Score: 0.283
  9. Cell cycle checkpoints, DNA damage/repair, and lung cancer risk. Cancer Res. 2005 Jan 01; 65(1):349-57.
    View in: PubMed
    Score: 0.262
  10. Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):3988-95.
    View in: PubMed
    Score: 0.253
  11. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003 Aug 20; 95(16):1211-8.
    View in: PubMed
    Score: 0.239
  12. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev. 2003 Aug; 12(8):689-98.
    View in: PubMed
    Score: 0.238
  13. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis. 2003 Mar; 24(3):505-9.
    View in: PubMed
    Score: 0.231
  14. Myeloperoxidase promoter region polymorphism and lung cancer risk. Methods Mol Med. 2003; 75:121-33.
    View in: PubMed
    Score: 0.228
  15. Assessment of insulin-like growth factors and mutagen sensitivity as predictors of lung cancer risk. Methods Mol Med. 2003; 75:279-87.
    View in: PubMed
    Score: 0.228
  16. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res. 2002 May 15; 62(10):2813-8.
    View in: PubMed
    Score: 0.219
  17. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst. 2002 May 01; 94(9):681-90.
    View in: PubMed
    Score: 0.218
  18. The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans. Carcinogenesis. 2001 Jun; 22(6):923-8.
    View in: PubMed
    Score: 0.205
  19. Dietary intake of isothiocyanates: evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000 Oct; 9(10):1017-20.
    View in: PubMed
    Score: 0.195
  20. D2 dopamine receptor gene polymorphisms among African-Americans and Mexican-Americans: a lung cancer case-control study. Cancer Epidemiol Biomarkers Prev. 2000 Oct; 9(10):1021-6.
    View in: PubMed
    Score: 0.195
  21. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst. 2000 May 03; 92(9):737-43.
    View in: PubMed
    Score: 0.190
  22. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. Growth Horm IGF Res. 2000 Apr; 10 Suppl A:S26-7.
    View in: PubMed
    Score: 0.189
  23. Associations among telomerase activity, p53 protein overexpression, and genetic instability in lung cancer. Br J Cancer. 1999 May; 80(3-4):453-7.
    View in: PubMed
    Score: 0.177
  24. Genetic susceptibility to tobacco carcinogenesis. Cancer Invest. 1999; 17(8):645-59.
    View in: PubMed
    Score: 0.173
  25. Chromosome 5 aberrations and genetic predisposition to lung cancer. Int J Cancer. 1998 Oct 23; 79(5):490-3.
    View in: PubMed
    Score: 0.171
  26. Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst. 1998 Sep 16; 90(18):1393-9.
    View in: PubMed
    Score: 0.170
  27. A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls. Cancer. 1998 Sep 15; 83(6):1118-27.
    View in: PubMed
    Score: 0.170
  28. Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res. 1998 Apr 15; 58(8):1605-8.
    View in: PubMed
    Score: 0.165
  29. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst. 1998 Mar 04; 90(5):358-63.
    View in: PubMed
    Score: 0.163
  30. Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. Cancer Epidemiol Biomarkers Prev. 1998 Jan; 7(1):13-8.
    View in: PubMed
    Score: 0.162
  31. Deletion in poly(ADP-ribose)polymerase pseudogene and lung cancer risk. Carcinogenesis. 1998 Jan; 19(1):93-8.
    View in: PubMed
    Score: 0.162
  32. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis. 1997 May; 18(5):967-73.
    View in: PubMed
    Score: 0.154
  33. Lung carcinoma patients with a family history of cancer and lymphocyte primary chromosome 9 aberrations. Cancer. 1997 Apr 15; 79(8):1527-32.
    View in: PubMed
    Score: 0.154
  34. Mutagen sensitivity exhibits a dose-response relationship in case-control studies. Cancer Epidemiol Biomarkers Prev. 1996 Jul; 5(7):577-8.
    View in: PubMed
    Score: 0.146
  35. A case-control study of wood dust exposure, mutagen sensitivity, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 1995 Sep; 4(6):583-8.
    View in: PubMed
    Score: 0.137
  36. A case-control study of nonrandom distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer cases. Cancer Res. 1995 Feb 01; 55(3):557-61.
    View in: PubMed
    Score: 0.132
  37. Wnt signaling pathway pharmacogenetics in non-small cell lung cancer. Pharmacogenomics J. 2014 Dec; 14(6):509-22.
    View in: PubMed
    Score: 0.127
  38. Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clin Pharmacol Ther. 2014 Sep; 96(3):360-369.
    View in: PubMed
    Score: 0.125
  39. Role of selected genetic variants in lung cancer risk in African Americans. J Thorac Oncol. 2013 Apr; 8(4):391-7.
    View in: PubMed
    Score: 0.116
  40. Sensation-seeking genes and physical activity in youth. Genes Brain Behav. 2013 Mar; 12(2):181-8.
    View in: PubMed
    Score: 0.114
  41. Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study. Clin Cancer Res. 2012 Nov 01; 18(21):5983-91.
    View in: PubMed
    Score: 0.112
  42. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res. 2012 Jul 01; 18(13):3705-13.
    View in: PubMed
    Score: 0.109
  43. Multistage analysis of variants in the inflammation pathway and lung cancer risk in smokers. Cancer Epidemiol Biomarkers Prev. 2012 Jul; 21(7):1213-21.
    View in: PubMed
    Score: 0.109
  44. Cigarette experimentation in Mexican origin youth: psychosocial and genetic determinants. Cancer Epidemiol Biomarkers Prev. 2012 Jan; 21(1):228-38.
    View in: PubMed
    Score: 0.105
  45. Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. Carcinogenesis. 2011 Dec; 32(12):1867-71.
    View in: PubMed
    Score: 0.105
  46. Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis. 2011 Jul; 32(7):1050-6.
    View in: PubMed
    Score: 0.102
  47. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011 May 18; 103(10):817-25.
    View in: PubMed
    Score: 0.101
  48. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis. 2010 Dec; 31(12):2118-23.
    View in: PubMed
    Score: 0.097
  49. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010 Aug 25; 5(8):e12402.
    View in: PubMed
    Score: 0.097
  50. Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. J Natl Cancer Inst. 2010 Aug 04; 102(15):1199-205.
    View in: PubMed
    Score: 0.096
  51. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer. 2011 Jan; 71(1):82-8.
    View in: PubMed
    Score: 0.095
  52. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila). 2009 Jul; 2(7):617-24.
    View in: PubMed
    Score: 0.090
  53. Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. Cancer. 2008 Nov 01; 113(9):2488-95.
    View in: PubMed
    Score: 0.086
  54. Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med. 2008 Dec 01; 178(11):1164-72.
    View in: PubMed
    Score: 0.085
  55. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila). 2008 Sep; 1(4):250-4.
    View in: PubMed
    Score: 0.085
  56. Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst. 2008 Aug 06; 100(15):1104-12.
    View in: PubMed
    Score: 0.084
  57. Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. Eur J Cancer. 2008 Jul; 44(11):1603-11.
    View in: PubMed
    Score: 0.083
  58. Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1716-22.
    View in: PubMed
    Score: 0.082
  59. ATM sequence variants associate with susceptibility to non-small cell lung cancer. Int J Cancer. 2007 Nov 15; 121(10):2254-9.
    View in: PubMed
    Score: 0.080
  60. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res. 2007 Oct 01; 13(19):5974-81.
    View in: PubMed
    Score: 0.079
  61. Mutagen sensitivity and genetic variants in nucleotide excision repair pathway: genotype-phenotype correlation. Cancer Epidemiol Biomarkers Prev. 2007 Oct; 16(10):2065-71.
    View in: PubMed
    Score: 0.079
  62. Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1517-22.
    View in: PubMed
    Score: 0.078
  63. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res. 2007 Jul 01; 67(13):6520-7.
    View in: PubMed
    Score: 0.078
  64. Nucleotide excision repair pathway genes and oral premalignant lesions. Clin Cancer Res. 2007 Jun 15; 13(12):3753-8.
    View in: PubMed
    Score: 0.078
  65. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007 May 02; 99(9):715-26.
    View in: PubMed
    Score: 0.077
  66. Irradiation-induced telomerase activity and the risk of lung cancer: a pilot case-control study. Cancer. 2007 Mar 15; 109(6):1157-63.
    View in: PubMed
    Score: 0.076
  67. Differential induction in telomerase activity among bladder cancer patients and controls on gamma-radiation. Cancer Epidemiol Biomarkers Prev. 2007 Mar; 16(3):606-9.
    View in: PubMed
    Score: 0.076
  68. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Dec 15; 12(24):7329-38.
    View in: PubMed
    Score: 0.075
  69. Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Oct 01; 12(19):5720-5.
    View in: PubMed
    Score: 0.074
  70. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin Genet. 2006 Sep; 70(3):240-5.
    View in: PubMed
    Score: 0.074
  71. Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis. 2007 Feb; 28(2):350-5.
    View in: PubMed
    Score: 0.073
  72. Bladder cancer risk as modified by family history and smoking. Cancer. 2006 Aug 15; 107(4):705-11.
    View in: PubMed
    Score: 0.073
  73. Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res. 2006 Jun 15; 66(12):5993-6.
    View in: PubMed
    Score: 0.073
  74. Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. Carcinogenesis. 2006 Oct; 27(10):2034-7.
    View in: PubMed
    Score: 0.072
  75. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006 Jan 15; 106(2):441-7.
    View in: PubMed
    Score: 0.071
  76. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2006 Jan; 15(1):158-61.
    View in: PubMed
    Score: 0.070
  77. Dietary phytoestrogens and lung cancer risk. JAMA. 2005 Sep 28; 294(12):1493-504.
    View in: PubMed
    Score: 0.069
  78. A modified host cell reactivation assay to measure DNA repair capacity for removing 4-aminobiphenyl adducts: a pilot study of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1832-6.
    View in: PubMed
    Score: 0.068
  79. Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation ot recurrence. Cancer. 2005 Jul 01; 104(1):30-5.
    View in: PubMed
    Score: 0.068
  80. Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study. Carcinogenesis. 2005 Oct; 26(10):1741-7.
    View in: PubMed
    Score: 0.067
  81. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8.
    View in: PubMed
    Score: 0.067
  82. An association between a NQO1 genetic polymorphism and risk of lung cancer. Mutat Res. 2005 Apr 04; 582(1-2):71-8.
    View in: PubMed
    Score: 0.067
  83. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):878-84.
    View in: PubMed
    Score: 0.067
  84. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S92-8.
    View in: PubMed
    Score: 0.067
  85. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol. 2005 Mar 01; 161(5):412-22.
    View in: PubMed
    Score: 0.066
  86. Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol. 2005 Jan 10; 23(2):267-75.
    View in: PubMed
    Score: 0.066
  87. Case-control analysis of dietary folate and risk of bladder cancer. Nutr Cancer. 2005; 53(2):144-51.
    View in: PubMed
    Score: 0.066
  88. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer. 2004 Dec 15; 101(12):2837-42.
    View in: PubMed
    Score: 0.065
  89. Dietary carotenoids and genetic instability modify bladder cancer risk. J Nutr. 2004 Dec; 134(12):3362-9.
    View in: PubMed
    Score: 0.065
  90. Specific chromosome aberrations in peripheral blood lymphocytes are associated with risk of bladder cancer. Genes Chromosomes Cancer. 2004 Dec; 41(4):379-89.
    View in: PubMed
    Score: 0.065
  91. Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer. Genes Chromosomes Cancer. 2004 Dec; 41(4):330-8.
    View in: PubMed
    Score: 0.065
  92. Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet. 2004 Aug; 5(8):589-97.
    View in: PubMed
    Score: 0.064
  93. Methyl-CpG-binding domain 2: a protective role in bladder carcinoma. Cancer. 2004 May 01; 100(9):1853-8.
    View in: PubMed
    Score: 0.063
  94. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. Carcinogenesis. 2004 Sep; 25(9):1639-47.
    View in: PubMed
    Score: 0.063
  95. An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res. 2004 Mar 15; 64(6):2251-7.
    View in: PubMed
    Score: 0.062
  96. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):113-23.
    View in: PubMed
    Score: 0.061
  97. XRCC3 genetic polymorphism, smoking, and lung carcinoma risk in minority populations. Cancer. 2003 Oct 15; 98(8):1701-6.
    View in: PubMed
    Score: 0.060
  98. Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res. 2003 Aug 15; 9(9):3356-61.
    View in: PubMed
    Score: 0.060
  99. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst). 2003 Aug 12; 2(8):901-8.
    View in: PubMed
    Score: 0.060
  100. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res. 2003 Apr 20; 536(1-2):131-7.
    View in: PubMed
    Score: 0.058
  101. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst. 2003 Apr 02; 95(7):540-7.
    View in: PubMed
    Score: 0.058
  102. Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. Lung Cancer. 2003 Apr; 40(1):25-32.
    View in: PubMed
    Score: 0.058
  103. Death receptor 4 and bladder cancer risk. Cancer Res. 2003 Mar 15; 63(6):1157-9.
    View in: PubMed
    Score: 0.058
  104. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control. 2003 Mar; 14(2):131-8.
    View in: PubMed
    Score: 0.058
  105. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol. 2003 Feb; 169(2):714-7.
    View in: PubMed
    Score: 0.057
  106. A case-control analysis of lymphocytic chromosome 9 aberrations in lung cancer. Int J Cancer. 2002 Dec 10; 102(5):536-40.
    View in: PubMed
    Score: 0.057
  107. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev. 2002 Nov; 11(11):1413-8.
    View in: PubMed
    Score: 0.056
  108. BPDE-induced lymphocytic 3p21.3 aberrations may predict head and neck carcinoma risk. Cancer. 2002 Aug 01; 95(3):563-8.
    View in: PubMed
    Score: 0.055
  109. Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiol Biomarkers Prev. 2002 Aug; 11(8):758-66.
    View in: PubMed
    Score: 0.055
  110. Genetic instability of specific chromosomes associated with a family history of cancer. Cancer Genet Cytogenet. 2002 Jul 01; 136(1):73-7.
    View in: PubMed
    Score: 0.055
  111. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer. 2002 Jul; 37(1):35-40.
    View in: PubMed
    Score: 0.055
  112. Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk. Am J Ind Med. 2002 Jul; 42(1):29-37.
    View in: PubMed
    Score: 0.055
  113. Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer. 2002 Feb; 35(2):137-42.
    View in: PubMed
    Score: 0.054
  114. Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-Hispanic whites. Mol Carcinog. 2002 Feb; 33(2):99-104.
    View in: PubMed
    Score: 0.054
  115. Modification of lung cancer susceptibility by green tea extract as measured by the comet assay. Cancer Detect Prev. 2002; 26(6):411-8.
    View in: PubMed
    Score: 0.053
  116. Gamma-radiation-induced G2 delay, apoptosis, and p53 response as potential susceptibility markers for lung cancer. Cancer Res. 2001 Nov 01; 61(21):7819-24.
    View in: PubMed
    Score: 0.053
  117. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001 Nov 01; 61(21):7825-9.
    View in: PubMed
    Score: 0.053
  118. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 2001 Feb 15; 61(4):1354-7.
    View in: PubMed
    Score: 0.050
  119. Gamma-radiation-induced single cell DNA damage as a measure of susceptibility to lung cancer: a preliminary report. Int J Oncol. 2000 Aug; 17(2):399-404.
    View in: PubMed
    Score: 0.048
  120. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis. 2000 Jun; 21(6):1163-6.
    View in: PubMed
    Score: 0.048
  121. Ethnic differences in poly(ADP-ribose) polymerase pseudogene genotype distribution and association with lung cancer risk. Carcinogenesis. 1999 Aug; 20(8):1465-9.
    View in: PubMed
    Score: 0.045
  122. Three measures of mutagen sensitivity in a cancer-free population. Cancer Genet Cytogenet. 1999 Apr; 110(1):65-9.
    View in: PubMed
    Score: 0.044
  123. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst. 1999 Jan 20; 91(2):151-6.
    View in: PubMed
    Score: 0.043
  124. Mutagen sensitivity as a susceptibility marker for human hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 1998 Jul; 7(7):567-70.
    View in: PubMed
    Score: 0.042
  125. A clinical trial to evaluate the effect of vitamin C supplementation on in vitro mutagen sensitivity. The University of Texas M. D. Anderson Clinical Community Oncology Program Network. Cancer Epidemiol Biomarkers Prev. 1997 Jul; 6(7):537-42.
    View in: PubMed
    Score: 0.039
  126. Survival of cells with bleomycin-induced chromosomal lesions in the cultured lymphocytes of lung cancer patients. Cancer Epidemiol Biomarkers Prev. 1996 Jul; 5(7):527-32.
    View in: PubMed
    Score: 0.036
  127. Mutagen sensitivity as a marker of cancer susceptibility. J Cell Biochem Suppl. 1996; 25:80-4.
    View in: PubMed
    Score: 0.035
  128. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis. 1995 Sep; 16(9):2205-8.
    View in: PubMed
    Score: 0.034
  129. Characterization of large structural genetic mosaicism in human autosomes. Am J Hum Genet. 2015 Mar 05; 96(3):487-97.
    View in: PubMed
    Score: 0.033
  130. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev. 1995 Mar; 4(2):99-103.
    View in: PubMed
    Score: 0.033
  131. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014 Jul; 46(7):736-41.
    View in: PubMed
    Score: 0.032
  132. Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes. Support Care Cancer. 2013 Nov; 21(11):3117-25.
    View in: PubMed
    Score: 0.030
  133. A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet. 2013 Jun; 45(6):690-6.
    View in: PubMed
    Score: 0.029
  134. Investigating multiple candidate genes and nutrients in the folate metabolism pathway to detect genetic and nutritional risk factors for lung cancer. PLoS One. 2013; 8(1):e53475.
    View in: PubMed
    Score: 0.029
  135. Fine-mapping of the 5p15.33, 6p22.1-p21.31, and 15q25.1 regions identifies functional and histology-specific lung cancer susceptibility loci in African-Americans. Cancer Epidemiol Biomarkers Prev. 2013 Feb; 22(2):251-60.
    View in: PubMed
    Score: 0.028
  136. Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. J Pain Symptom Manage. 2013 Aug; 46(2):161-72.
    View in: PubMed
    Score: 0.028
  137. Association study of nicotinic acetylcholine receptor genes identifies a novel lung cancer susceptibility locus near CHRNA1 in African-Americans. Oncotarget. 2012 Nov; 3(11):1428-38.
    View in: PubMed
    Score: 0.028
  138. Method for evaluating multiple mediators: mediating effects of smoking and COPD on the association between the CHRNA5-A3 variant and lung cancer risk. PLoS One. 2012; 7(10):e47705.
    View in: PubMed
    Score: 0.028
  139. Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet. 2012 Nov 15; 21(22):4980-95.
    View in: PubMed
    Score: 0.028
  140. Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers. Arch Gen Psychiatry. 2012 Aug; 69(8):854-60.
    View in: PubMed
    Score: 0.028
  141. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012 May 06; 44(6):651-8.
    View in: PubMed
    Score: 0.027
  142. Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol. 2012 May 15; 175(10):1013-20.
    View in: PubMed
    Score: 0.027
  143. A case-control study of a sex-specific association between a 15q25 variant and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2603-9.
    View in: PubMed
    Score: 0.026
  144. Novel genetic variants in the chromosome 5p15.33 region associate with lung cancer risk. Carcinogenesis. 2011 Oct; 32(10):1493-9.
    View in: PubMed
    Score: 0.026
  145. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila). 2011 Feb; 4(2):185-93.
    View in: PubMed
    Score: 0.025
  146. Mediating effects of smoking and chronic obstructive pulmonary disease on the relation between the CHRNA5-A3 genetic locus and lung cancer risk. Cancer. 2010 Jul 15; 116(14):3458-62.
    View in: PubMed
    Score: 0.024
  147. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst. 2010 Jul 07; 102(13):959-71.
    View in: PubMed
    Score: 0.024
  148. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 2010 Apr; 11(4):321-30.
    View in: PubMed
    Score: 0.024
  149. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2636-42.
    View in: PubMed
    Score: 0.023
  150. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet. 2008 Dec; 40(12):1407-9.
    View in: PubMed
    Score: 0.021
  151. The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):3262-7.
    View in: PubMed
    Score: 0.021
  152. Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst. 2008 Sep 17; 100(18):1326-30.
    View in: PubMed
    Score: 0.021
  153. Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer. 2008 Jun 15; 112(12):2756-64.
    View in: PubMed
    Score: 0.021
  154. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008 May; 40(5):616-22.
    View in: PubMed
    Score: 0.021
  155. Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. Genet Med. 2007 Feb; 9(2):67-73.
    View in: PubMed
    Score: 0.019
  156. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis. Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15(10):1935-40.
    View in: PubMed
    Score: 0.019
  157. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer. 2006 Jun 15; 106(12):2636-44.
    View in: PubMed
    Score: 0.018
  158. Inflammatory gene polymorphisms influence risk of postoperative morbidity after lung resection. Ann Thorac Surg. 2005 May; 79(5):1704-10.
    View in: PubMed
    Score: 0.017
  159. Comparison of haplotype inference methods using genotypic data from unrelated individuals. Hum Hered. 2004; 58(2):63-8.
    View in: PubMed
    Score: 0.015
  160. Statistical models for analysis of cytogenetic biomarkers. J Investig Med. 2000 Jul; 48(4):281-6.
    View in: PubMed
    Score: 0.012
  161. Analysis of aromatic DNA adducts and 7,8-dihydro-8-oxo- 2'-deoxyguanosine in lymphocyte DNA from a case-control study of lung cancer involving minority populations. Mol Carcinog. 2000 Jan; 27(1):34-46.
    View in: PubMed
    Score: 0.012
  162. Correspondence re: M. T. Goodman et al., effects of beta-carotene and alpha-tocopherol on bleomycin-induced chromosomal damage. Cancer Epidemiol. Biomark. Prev., 7: 113-117, 1998. Cancer Epidemiol Biomarkers Prev. 1998 Aug; 7(8):729.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.